Antigen rapid test, from the pharmaceutical company BioJam, allows to detect if a person has COVID-19, in 15 minutes, from the first 24 hours of contagion. The pharmaceutical company has already notified INFARMED to put the test on the market.<\/p>\n\n\n
For the distribution of the NADAL COVID-19 Ag rapid antigen tests,<\/strong> the pharmaceutical company BioJam<\/strong> indicated that it has already notified INFARMED<\/strong>. The test allows detection, from the first 24 hours of infection, of a protein of the coronavirus that causes COVID-19, thus determining the infection.<\/p>\n\n\n These rapid tests allow filling a gap in the quick diagnosis in the early stage of infection, as they have a detection window similar to current PCR tests.<\/p>\n\n\n The tests do not require instrumentation, and the results are obtained in just 15 minutes, significantly reducing false positives caused by contamination from other tests.<\/p>\n\n\n The NADAL rapid antigen tests, manufactured in Germany, provide essential information at the time of the infection period when there is a higher risk of disease transmission. This rapid test \"constitutes a reliable and affordable tool for detecting infection outbreaks on a large scale, thus reducing the spread of the disease.\"<\/p>\n\n\n This diagnostic tool is based on a lateral flow system, which does not require instrumentation, meaning the test is performed with a simple device that detects the presence of a substance in a liquid sample without the need for specialized and expensive equipment.<\/p>\n\n\n